What do systematic reviews say?

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Single‐dose, preoperative MMC‐EMDA vs single‐dose, postoperative MMC‐PD

Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with single‐dose, postoperative MMC‐PD (low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  HR 0.99 [0.74, 1.32]
  1 study · 236 participants
  Low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Single‐dose, preoperative MMC‐EMDA vs TURBT alone

Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with TURBT alone (moderate certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  HR 1.06 [0.8, 1.4]
  1 study · 233 participants
  Moderate

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower disease‐specific survival compared with postoperative BCG induction and maintenance therapy (low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  HR 0.31 [0.12, 0.8]
  1 study · 212 participants
  Low